Is it time to move to multidrug combinations?
- PMID: 14625159
- DOI: 10.1016/j.amjhyper.2003.07.005
Is it time to move to multidrug combinations?
Abstract
The clinical benefit of aggressive blood pressure (BP) control in reducing adverse cardiovascular and renal outcomes is well documented. However, a majority of patients with hypertension remain poorly controlled with monotherapy and require two or more agents to achieve their _target BP levels. Patients with hypertension who also have diabetes or renal disease benefit from even lower BP _targets, but may be more difficult to treat and require three or more drugs to achieve control. Using two or more drugs, each at lower doses, is usually more effective and less commonly associated with adverse effects than higher doses of a single drug. With the increasing prevalence of diabetes and renal disease, the treatment of hypertensive patients with multidrug combinations will become even more common. Knowing how specific combinations can be used effectively will be an important component of the treatment strategy for hypertension.
Similar articles
-
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.J Hypertens. 2017 May;35(5):922-944. doi: 10.1097/HJH.0000000000001276. J Hypertens. 2017. PMID: 28141660 Review.
-
Renal protection in hypertensive patients: selection of antihypertensive therapy.Drugs. 2005;65 Suppl 2:29-39. doi: 10.2165/00003495-200565002-00005. Drugs. 2005. PMID: 16398060 Review.
-
Using fixed-dose combination therapies to achieve blood pressure goals.Clin Drug Investig. 2008;28(11):713-34. doi: 10.2165/00044011-200828110-00005. Clin Drug Investig. 2008. PMID: 18840014 Review.
-
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.Drugs. 2005;65(13):1893-914. doi: 10.2165/00003495-200565130-00011. Drugs. 2005. PMID: 16114984 Review.
-
The future of antihypertensive treatment.Am J Ther. 2007 Mar-Apr;14(2):121-34. doi: 10.1097/01.pap.0000249915.12185.58. Am J Ther. 2007. PMID: 17414579 Review.
Cited by
-
Combination therapy as first-line treatment for hypertension.Curr Hypertens Rep. 2004 Aug;6(4):267-72. doi: 10.1007/s11906-004-0020-x. Curr Hypertens Rep. 2004. PMID: 15257860 Review.
-
How Can Synergism of Traditional Medicines Benefit from Network Pharmacology?Molecules. 2017 Jul 7;22(7):1135. doi: 10.3390/molecules22071135. Molecules. 2017. PMID: 28686181 Free PMC article. Review.
-
The role and mechanism of TCM in the prevention and treatment of infectious diseases.Front Microbiol. 2023 Nov 14;14:1286364. doi: 10.3389/fmicb.2023.1286364. eCollection 2023. Front Microbiol. 2023. PMID: 38033575 Free PMC article. Review.
-
2009 Canadian Hypertension Education Program recommendations: an annual update.Can Fam Physician. 2009 Jul;55(7):697-700. Can Fam Physician. 2009. PMID: 19602652 Free PMC article. No abstract available.
-
Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement.Can J Cardiol. 2007 Aug;23(10):783-7. doi: 10.1016/s0828-282x(07)70827-9. Can J Cardiol. 2007. PMID: 17703255 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
